68 related articles for article (PubMed ID: 22291397)
1. The effects of thyrotropin-releasing hormone and scopolamine in Alzheimer's disease and normal volunteers.
Molchan SE; Mellow AM; Hill JL; Weingartner H; Martinez R; Vitiello B; Sunderland T
J Psychopharmacol; 1992 Jan; 6(4):489-500. PubMed ID: 22291397
[TBL] [Abstract][Full Text] [Related]
2. [Validation of the Short Cognitive Battery (B2C). Value in screening for Alzheimer's disease and depressive disorders in psychiatric practice].
Robert PH; Schuck S; Dubois B; Lépine JP; Gallarda T; Olié JP; Goni S; Troy S
Encephale; 2003; 29(3 Pt 1):266-72. PubMed ID: 12876552
[TBL] [Abstract][Full Text] [Related]
3. Effects of pyridostigmine and naloxone on the abnormal TSH response to TRH during starvation in humans.
Coiro V; Volpi R; Capretti L; Caffarri G; Colla R; Chiodera P
J Investig Med; 1999 May; 47(5):227-31. PubMed ID: 10361382
[TBL] [Abstract][Full Text] [Related]
4. Nefiracetam ameliorates associative learning impairment in the scopolamine-injected older rabbit.
Pak J; Green J; Heifets B; Pak M; Woodruff-Pak D
Med Sci Monit; 2002 Apr; 8(4):BR105-12. PubMed ID: 11951055
[TBL] [Abstract][Full Text] [Related]
5. Serum thyrotropin responses to synthetic thyrotropin-releasing hormone in normal children and hypopituitary patients. A new test to distinguish primary releasing hormone deficiency from primary pituitary hormone deficiency.
Foley TP; Owings J; Hayford JT; Blizzard RM
J Clin Invest; 1972 Feb; 51(2):431-7. PubMed ID: 4621544
[TBL] [Abstract][Full Text] [Related]
6. The effects of a glycine reuptake inhibitor R231857 on the central nervous system and on scopolamine-induced impairments in cognitive and psychomotor function in healthy subjects.
Liem-Moolenaar M; Zoethout RW; de Boer P; Schmidt M; de Kam ML; Cohen AF; Franson KL; van Gerven JM
J Psychopharmacol; 2010 Nov; 24(11):1681-7. PubMed ID: 19648218
[TBL] [Abstract][Full Text] [Related]
7. TRH attenuates scopolamine-induced memory impairment in humans.
Molchan SE; Mellow AM; Lawlor BA; Weingartner HJ; Cohen RM; Cohen MR; Sunderland T
Psychopharmacology (Berl); 1990; 100(1):84-9. PubMed ID: 2104988
[TBL] [Abstract][Full Text] [Related]
8. Scopolamine effects on the pressor response to thyrotropin-releasing hormone in humans.
Molchan SE; Hill JL; Minichiello M; Vitiello B; Sunderland T
Life Sci; 1994; 54(13):933-8. PubMed ID: 8139380
[TBL] [Abstract][Full Text] [Related]
9. Effect of pyridostigmine on the thyroid-stimulating hormone response to thyrotropin-releasing hormone in abstinent alcoholics.
Coiro V; Vescovi PP
Alcohol Clin Exp Res; 1997 Oct; 21(7):1308-11. PubMed ID: 9347094
[TBL] [Abstract][Full Text] [Related]
10. Memory and attention in patients with senile dementia of the Alzheimer type and in normal elderly subjects.
Lines CR; Dawson C; Preston GC; Reich S; Foster C; Traub M
J Clin Exp Neuropsychol; 1991 Sep; 13(5):691-702. PubMed ID: 1955525
[TBL] [Abstract][Full Text] [Related]
11. Probing peripheral and central cholinergic system responses.
Naranjo CA; Fourie J; Herrmann N; Lanctôt KL; Birt C; Yau KK
J Psychiatry Neurosci; 2000 Sep; 25(4):325-36. PubMed ID: 11022397
[TBL] [Abstract][Full Text] [Related]
12. The scopolamine model of dementia: determination of central cholinomimetic effects of physostigmine on cognition and biochemical markers in man.
Preston GC; Brazell C; Ward C; Broks P; Traub M; Stahl SM
J Psychopharmacol; 1988 Jan; 2(2):67-79. PubMed ID: 22155841
[TBL] [Abstract][Full Text] [Related]
13. Estradiol treatment and its interaction with the cholinergic system: effects on cognitive function in healthy young women.
Bartholomeusz CF; Wesnes KA; Kulkarni J; Vitetta L; Croft RJ; Nathan PJ
Horm Behav; 2008 Nov; 54(5):684-93. PubMed ID: 18706905
[TBL] [Abstract][Full Text] [Related]
14. Acute effects of high-dose thyrotropin releasing hormone infusions in Alzheimer's disease.
Mellow AM; Sunderland T; Cohen RM; Lawlor BA; Hill JL; Newhouse PA; Cohen MR; Murphy DL
Psychopharmacology (Berl); 1989; 98(3):403-7. PubMed ID: 2501817
[TBL] [Abstract][Full Text] [Related]
15. Anticholinergic challenge and cognitive functions: a comparison between young and elderly normal subjects.
Zemishlany Z; Thorne AE
Isr J Psychiatry Relat Sci; 1991; 28(3):32-41. PubMed ID: 1800456
[TBL] [Abstract][Full Text] [Related]
16. The effects of the glycine reuptake inhibitor R213129 on the central nervous system and on scopolamine-induced impairments in psychomotor and cognitive function in healthy subjects.
Liem-Moolenaar M; Zoethout RW; de Boer P; Schmidt M; de Kam ML; Cohen AF; Franson KL; van Gerven JM
J Psychopharmacol; 2010 Nov; 24(11):1671-9. PubMed ID: 20142308
[TBL] [Abstract][Full Text] [Related]
17. Human prolactin and thyrotropin concentrations in the serums of normal and hypopituitary children before and after the administration of synthetic thyrotropin-releasing hormone.
Foley TP; Jacobs LS; Hoffman W; Daughaday WH; Blizzard RM
J Clin Invest; 1972 Aug; 51(8):2143-50. PubMed ID: 4626583
[TBL] [Abstract][Full Text] [Related]
18. NTP Toxicology and Carcinogenesis Studies of Scopolamine Hydrobromide Trihydrate (CAS No. 6533-68-2) in F344 Rats and B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1997 Mar; 445():1-277. PubMed ID: 12594530
[TBL] [Abstract][Full Text] [Related]
19. Reversal of scopolamine-induced deficits with a single dose of donepezil, an acetylcholinesterase inhibitor.
Snyder PJ; Bednar MM; Cromer JR; Maruff P
Alzheimers Dement; 2005 Oct; 1(2):126-35. PubMed ID: 19595845
[TBL] [Abstract][Full Text] [Related]
20. Scopolamine reduces frontal cortex perfusion.
Honer WG; Prohovnik I; Smith G; Lucas LR
J Cereb Blood Flow Metab; 1988 Oct; 8(5):635-41. PubMed ID: 3417793
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
